JAK–STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression

Julian Mohrherr1,2, Marcel Haber2, Kristina Breitenecker1,2, Petra Aigner1,2, Stefan Moritsch3, Viktor Voronin2, Robert Efer2,3, Richard Morigail2,4, Dagmar Stoiber1,2, Balázs Győrffy6, Luka Brčić7, Viktória László8, Balázs Döme8,9,10,11, Judit Moldvay10,12, Katalin Dezső13, Martin Bilban14,15, Helmut Popper7, Herwig P. Moll1* and Emilio Casanova2,4

1Department of Physiology, Center of Physiology and Pharmacology & Comprehensive Cancer Center (CCC), Medical University of Vienna, Vienna, Austria
2Ludwig Boltzmann Institute for Cancer Research (LBI-CR), Vienna, Austria
3Institute of Cancer Research, Medical University of Vienna & Comprehensive Cancer Center (CCC), Vienna, Austria
4Institute of Animal Breeding and Genetics, University of Veterinary Medicine, Vienna, Austria
5Medical University of Vienna, Vienna, Austria
6MTA TK Lendület Cancer Biomarker Research Group, Institute of Enzymology, and Second Department of Pediatrics, Semmelweis University, Budapest, Hungary
7Diagnostic & Research Institute of Pathology, Medical University of Graz, Graz, Austria
8Division of Thoracic Surgery, Department of Surgery & Comprehensive Cancer Center (CCC), Medical University of Vienna, Vienna, Austria
9Division of Biomedical Imaging and Image-guided Therapy, Division of Molecular and Gender Imaging, Medical University of Vienna, Vienna, Austria
10Department of Tumor Biology, National Korányi Institute of Pulmonology, Semmelweis University, Budapest, Hungary
11Department of Thoracic Surgery, National Institute of Oncology and Semmelweis University, Budapest, Hungary
12SE-NAP Brain Metastasis Research Group, 2nd Department of Pathology, Semmelweis University, Budapest, Hungary
13First Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary
14Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
15Core Facilities, Medical University of Vienna, Vienna, Austria

Oncogenic K-RAS has been difficult to target and currently there is no K-RAS-based targeted therapy available for patients suffering from K-RAS-driven lung adenocarcinoma (AC). Alternatively, targeting K-RAS-downstream effectors, K-RAS-cooperating signaling pathways or cancer hallmarks, such as tumor-promoting inflammation, has been shown to be a promising therapeutic strategy. Since the JAK–STAT pathway is considered to be a central player in inflammation-mediated tumorigenesis, we investigated here the implication of JAK–STAT signaling and the therapeutic potential of JAK1/2 inhibition in K-RAS-driven lung

*H.P.M. and E.C. are equal senior authors

Additional Supporting Information may be found in the online version of this article.

Key words: non-small cell lung cancer, lung adenocarcinoma (AC), Kirsten rat sarcoma viral proto-oncogene (K-RAS), Janus kinase (JAK), ruxolitinib, cell-line derived xenografts, genetically engineered mouse models, tumor microenvironment (TME), tumor promoting inflammation

Abbreviations: AC: adenocarcinoma; ACTB: actin beta; ANOVA: one-way analysis of variance; CXCL1: chemokine (C-X-C motif) ligand 1; EGFR: epidermal growth factor receptor; GO: gene ontology; GSEA: gene set enrichment analysis; IL: interleukin; JAK: Janus kinase; K-RAS: Kirsten rat sarcoma viral proto-oncogene; MDSCs: myeloid derived suppressor cells; mRNA: messenger RNA; NKS: natural killer cells; PD-L1: programmed cell death ligand 1; RNA-seq: RNA sequencing; STAT: signal transducer and activator of transcription; TBP: TATA-box binding protein; TME: tumor microenvironment; TNF: tumor necrosis factor; VEGF: vascular endothelial growth factor; WT: wild-type

Conflict of Interest: The authors declare no potential conflict of interest.

Grant sponsor: Austrian Science Fund; Grant numbers: FWF-P 25599-B19, P29222-B28; Grant sponsor: National Research, Development and Innovation Office, Hungary; Grant numbers: KH-129581, NVK_16-1-2016-0037

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

DOI: 10.1002/ijc.32624

History: Received 19 Feb 2019; Accepted 22 Jul 2019; Online 12 Aug 2019

Correspondence to: Herwig P. Moll, Department of Physiology, Center of Physiology and Pharmacology, Comprehensive Cancer Center, Medical University of Vienna, AT-1090 Vienna, Austria. Tel.: +43140160-71230, E-mail: herwig.moll@meduniwien.ac.at
AC. Our data showed that JAK1 and JAK2 are activated in human lung AC and that increased activation of JAK–STAT signaling correlated with disease progression and K-RAS activity in human lung AC. Accordingly, administration of the JAK1/2 selective tyrosine kinase inhibitor ruxolitinib reduced proliferation of tumor cells and effectively reduced tumor progression in immunodeficient and immunocompetent mouse models of K-RAS-driven lung AC. Notably, JAK1/2 inhibition led to the establishment of an antitumorogenic tumor microenvironment, characterized by decreased levels of tumor-promoting chemokines and cytokines and reduced numbers of infiltrating myeloid derived suppressor cells, thereby impairing tumor growth. Taken together, we identified JAK1/2 inhibition as promising therapy for K-RAS-driven lung AC.

What’s new?

A drug that inhibits the JAK–STAT pathway may score a hit against K-RAS driven lung cancer. Here, the authors investigated the JAK STAT pathway as a possible target in lung adenocarcinoma because of its role in inflammation-mediated tumorigenesis. First, they showed that JAK1 and JAK2 are both activated in lung adenocarcinoma patients with oncogenic mutations in K-RAS. Next, they treated the tumors with ruxolitinib, which inhibits JAK1/2. The drug successfully slowed tumor proliferation and progression in immunocompetent mouse models. Furthermore, treatment with ruxolitinib reduced the tumor-promoting factors present in the microenvironment.

Introduction

Lung cancer is still the leading cause of cancer-related deaths worldwide in both men and women. Histologically, lung cancer can be subdivided into small cell lung cancer and non-small cell lung cancer, with lung adenocarcinoma (AC) being the most abundant among the non-small cell lung cancer subtype. Roughly 50% of lung ACs harbor oncogenic mutations in the V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (K-RAS) or epidermal growth factor receptor (EGFR). While EGFR tyrosine kinase inhibitors, such as erlotinib, gefitinib or afatinib, are part of the clinical routine to treat EGFR-mutated lung AC patients, the development of K-RAS inhibitors has been less successful so far, with no K-RAS-based targeted therapy being clinically approved. Hence, targeting alternative tumor drivers fueling K-RAS-mediated lung tumorigenesis such as tumor-promoting inflammation and K-RAS downstream effector pathways are considered to be a promising treatment strategy.

Given the pivotal role of Janus kinase (JAK) activation in tumorigenic inflammation and its oncogenic functions, JAKs represent attractive therapeutic targets in tumorigenesis. The JAK family is composed of four members (JAK1, JAK2, JAK3 and tyrosine kinase 2) and couples extracellular stimuli with gene transcription. Upon cytokine binding to their cognate receptors, JAKs become activated and phosphorylate downstream signal transducer and activator of transcription (STAT) molecules, ultimately leading to nuclear translocation and transcription of various target genes involved in cell cycle regulation, angiogenesis, apoptosis, tumor invasion and metastasis. JAK signaling either promotes or suppresses tumorigenesis in a tumor cell intrinsic manner. Indeed, K-RAS-mutated lung AC cells secrete pro-inflammatory cytokines including interleukin (IL)-6 that activate JAK1 and JAK2 via glycoprotein 130 in an autocrine loop, thereby promoting tumor cell survival. On the other hand, genetic deletion of STAT3, a key signaling mediator of JAK1/2, enhances K-RAS-driven lung tumorigenesis, and activation of the interferon/JAK/STAT axis induces cell apoptosis and suppresses tumorigenesis in various experimental tumor models.

In addition to these tumor-cell intrinsic effects, JAK signaling is also substantially involved in shaping the tumor microenvironment (TME) by modulating T, natural killer (NK) and dendritic cell functions. In tumor cells, JAK activation in the TME and its role in tumorigenesis is controversially discussed. While JAK1/2 inhibition impairs NK-cell function and NK mediated antitumor immunity and hence indirectly facilitates tumor metastatic spread, targeting the JAK–STAT axis has also been proposed as a potential effective strategy to reduce levels of tumor-promoting immunosuppressive myeloid derived suppressor cells (MDSCs), thereby counteracting malignant progression. Furthermore, IL6/JAK/STAT3, as well as interferon-γ/JAK/STAT1 signaling pathways have also been described to induce programmed cell death 1 and or programmed cell death 1 ligand 1 (PD-L1) expression and, therefore, to promote tumor immune escape. Taken together, these reports indicate that JAKs may have opposite functions in tumorigenesis depending on the cellular context.

Clinical trials investigating JAK inhibition in particular for EGFR-mutated lung cancers are ongoing. These studies combine the JAK inhibitors ruxolitinib, itacitinib and AZD4205 with the EGFR tyrosine kinase inhibitors erlotinib (NCT02155465), afatinib (NCT02145637) and osimertinib (NCT02917993, NCT03450330). By contrast, JAK targeting in K-RAS-mutated lung ACs has not been thoroughly investigated so far. Notably, a recent clinical trial showed positive results when combining ruxolitinib and chemotherapies in non-small cell lung cancer patients, but the K-RAS mutation status is not available (NCT02119650). Thus, to complement these clinical studies, we addressed the role of JAK1/2 in...
K-RAS-driven lung AC pathogenesis. By using human tumor samples and experimental mouse models, we show that JAK1/2 are activated in K-RAS-driven lung AC and promote tumor growth and progression by establishing a protumorigenic TME. Importantly, pharmacological inhibition of JAK1/2 with the tyrosine kinase inhibitor ruxolitinib reverts the protumorigenic TME and impairs tumorigenesis.

Materials and Methods

Human data
For gene expression analysis, we took advantage of the publicly available Illumina microarray data set, which contains biopsies of K-RAS-mutated lung AC tissue and adjacent healthy tissue (GSE75037).22 To determine JAK1 and JAK2 mRNA expression levels, we used probes as depicted in Table S1. As a second cohort, we used gene expression data from K-RAS-mutated lung AC patients included in the Cancer Genome Atlas (n = 154).23 Gene set enrichment analysis (GSEA) was performed according to the provider’s protocol and permutations were set to 1,000.24 Gene sets were downloaded from the Molecular Signature Database (http://software.broadinstitute.org/gsea/msigdb/index.jsp). To determine the prognostic value of chemo/cytokine related genes upon ruxolitinib treatment for human lung ACs pathogenesis, we used the KM-Plotter online tool.25 In addition, gene expression data of K-RAS-mutated lung AC patients with available survival data included in the Cancer Genome Atlas were analyzed (n = 150).23 We have run the analysis by evaluating all possible cutoff values and the best performing value was used as the cutoff in the final analysis. False discovery rate was computed to correct for multiple testing, and only results having a false discovery rate below 1% was accepted as statistically significant. Analysis was performed using the mean expression of the genes included in the multigene signature, and all utilized Probe-IDs are shown in Table S2.

For immunohistochemical analysis, we generated tissue microarrays from two independent lung AC patient cohorts. Cohort A includes biopsies from lung AC patients where information about the mutational K-RAS status was not available (pJAK1 n = 303, pJAK2 n = 318). Cohort B consists of biopsies of lung AC patients positive for K-RAS mutation (pJAK1 n = 26, pJAK2 n = 24). Analysis was done with prior approval by the institutional ethical committee. For detection of JAK1 or JAK2 tyrosine phosphorylation the tissue microarrays were stained with a pJAK1 (1:200, Y1022, #PA537617, Thermo Fisher Scientific, Waltham, MA) and a pJAK2 (1:200, Y1007 and Y1008, #32101, Abcam, Cambridge, UK) antibody. Histoscores were determined according to staining intensities and percentage of positive tumor cells by a board-certified pathologist (H.P.).26

Cell lines
The human K-RAS-mutated lung AC cell lines A549 and A427 were grown in RPMI medium (Gibco, Grand Island, NY) supplemented with 10% FBS, 2 mM glutamine (Gibco), penicillin (50 U/ml, Gibco) and streptomycin (50 μg/ml, Gibco). A549 and A427 cell lines were obtained from American Type Culture Collection, and cells were profiled for authentication (Eurofins Genomics, Luxembourg). Cells were tested to be free of mycoplasma contaminations twice a year. For experiments, cells were harvested at ~70% confluency, and the number of viable cells was determined using a CASY counter (Roche, Basel, Switzerland).

Animal husbandry and experiments
For subcutaneous xenograft experiments using the K-RAS-mutated human lung AC cell lines A549 and A427, 1 × 10⁶ cells were mixed 1:2 with Matrigel (Corning, Corning, NY) and injected into the right and left flank of immunodeficient NOD scid gamma mice older than 6 weeks of age. Tumor volume was measured using a caliper and tumor volume was calculated using the formula [(length × width²) × 0.52] as previously established in our laboratory.27 K-rasLSL-G12D (K) mice as well as K-rasLSL-G12Dp53+/fl (KP) mice, both bred on a C57Bl/6 background, served as genetically engineered mouse models for autochthonous lung AC.28 Genotyping of the transgenes was performed using primers depicted in Table S3. Induction of lung tumors in these genetically engineered mouse models was achieved through intranasal inhalation of a Cre-recombinase expressing adenovirus (Ad.Cre) in 8–12 week old mice using 2.5 × 10⁹ plaque-forming units. Inhalation of K and KP mice with Ad.Cre triggers K-rasLSL-G12D activation in lung epithelial cells resulting in formation of p53 expressing (K) or deficient (KP) lung ACs. Ad.Cre was purchased from the Viral Vector Core (University of Iowa). For treatment of mice with the JAK1/2 inhibitor ruxolitinib (LC Labs, Woburn, MA), the inhibitor was suspended in 0.5% (w/v) methylcellulose solution. Mice were treated via oral gavage with vehicle (ctrl, 0.5% Methylcellulose) or ruxolitinib (Ruxo) at 90 mg/kg twice a day (BID), 7 days per week for the indicated experimental time period. Treatment of mice was paused if any signs of distress occurred.18 All experimental protocols as well as animal maintenance and breeding described above, followed ethical guidelines and were approved by the Austrian Federal Ministry of Science, Research and Economy.

Histology
At the experimental endpoint, subcutaneously engrafted tumor tissue or lung tissue was retrieved and fixed in 2% buffered formaldehyde at 4°C for 24 hr and embedded in paraffin after dehydration. Five micron sections were used for analysis. To determine tumor area, lung sections were stained with hematoxylin and eosin and subsequently scanned using TissueFaxes (TissueGnostics, Vienna, Austria) software. Tumor area and number were quantified using HistoQuest (TissueGnostics) software. Tumor grades were determined by a board-certified pathologist Katalin Dezso (K.D.) according to DuPage et al.28 For immunohistochemistry, standard protocols were applied, using antibodies against pSTAT3 (1:200,Y705, #9145, Cell Signaling, Danvers, MA), Ki67 (1:400, Cell Signaling #12202 or 1:200, #13191, Cell Signaling Biotech, Danvers, MA), and EphB2 (1:50, Cell Signaling #4007 or 1:200, #4849, Cell Signaling).
genes (based on log2 fold changes) in the ruxolitinib treated analysis, the Enrichr web tool was used (http://amp. Int. J. Cancer: 3376–3388 (2019) © 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC
more advanced disease revealed increased JAK1/2 expression levels in the latter group, which reached significance for JAK1 (Fig. 1a). In line with these data, we found activation of the JAK–STAT pathway in patients with more advanced lung AC (i.e., in stage II disease), as determined by GSEA (Fig. 1b). Next, we confirmed these data in K-RAS mutated lung AC patients from a different cohort published by the Cancer Genome Atlas. Indeed, we found a significant correlation of JAK1 and JAK2 mRNA expression levels with enrichment of K-RAS signaling in lung AC patients (Figs. 1c and 1d). Moreover, we noticed a significant increase of JAK1 and JAK2 mRNA expression in tumors of late stage patients with oncogenic K-RAS mutations compared to patients harboring K-RAS WT tumors, which was not observed in early stage patients (Figs. S1a and S1b).

However, using mRNA expression data of bulk tumor tissue does not allow distinguishing between tumor and stromal cells. Hence, we performed immunohistochemistry for activated JAK1 and JAK2 in biopsies of lung AC patients from two independent cohorts (cohorts A&B, consisting of unselected and K-RAS mutated samples, respectively). Indeed, JAK1 and JAK2 were activated/phosphorylated in tumor cells of lung AC patients as determined by a pathologist (H.P.). In the stroma, a positive reaction for JAK1 and JAK2 was mainly found in lymphocytes (Figs. 1e and 1f).

Taken together, these data indicated that JAK1/2 inhibition blocks K-RAS driven lung tumorigenesis in vivo

Next, we assessed the potential benefits of pharmacological JAK1/2 inhibition in K-RAS-driven lung AC using the JAK1/2 selective tyrosine kinase inhibitor ruxolitinib. We performed subcutaneous engraftments of phosphorylated human lung AC cells harboring oncogenic K-RAS mutations into immunodeficient NOD scid gamma mice. Intriguingly, ruxolitinib treatment significantly attenuated growth of the human K-RAS (Fig. 2a–2c), and impaired growth of A427 (K-RAS (Fig. 2d) transplanted cells (Figs. S2a and S2b). Immunohistochemistry analysis of proliferation and apoptosis markers within tumors
revealed that JAK inhibition significantly reduced proliferation and slightly increased apoptosis of transplanted lung AC cells (Figs. 2d and 2e). JAK1/2 inhibition in tumor cells of ruxolitinib treated mice was efficient, since activation of the downstream effector STAT3 was almost absent after tyrosine kinase inhibitor treatment (Figs. 2d and 2e). Accordingly, ruxolitinib treatment impaired a well-described autocrine oncogenic activation loop in this model. Indeed, tumor cell-derived expression of pro-inflammatory cytokines IL-6 and IL-1β was significantly decreased in the ruxolitinib treated group, as verified by quantitative real-time PCR using primers specific for the human transcripts of these cytokines (Fig. 2f). Notably, the ruxolitinib dose used in our experiments was generally well tolerated by the experimental mice, and we did not observe any significant body weight loss in the treated groups (Fig. S2c). Since abrogation of JAK signaling may also impair angiogenesis, we checked expression of the angiogenic markers Vegfa and Hif1a and evaluated numbers of cluster of differentiation 31+ vessels, but we did not observe changes upon ruxolitinib treatment (Figs. S2d and S2e).

**Ruxolitinib attenuates tumorigenesis of autochthonous K-RAS-driven lung AC**

Although cell-line-derived xenograft models have the advantage to study tumors of human origin, a major drawback of these models is the absence of a functional immune system. However, this is a critical factor in our study, since ruxolitinib was reported...
Figure 3. Ruxolitinib attenuates tumorigenesis of autochthonous K-RAS-driven lung AC. (a) Left panel: representative pictures of hematoxylin and eosin stained lung sections of vehicle control (ctrl) or ruxolitinib (Ruxo) treated K-rasG12D (K) mice (n = 7 per group) and K-rasG12D;p53fl/fl (KP) mice (n = 8 per group). Treatment was started 1 week post tumor initiation, and continued for 10 weeks, with ruxolitinib being administered at 90 mg/kg body weight, seven times per week, BID (scale bars: 400 μm). Right panel: quantitation of hematoxylin and eosin stained lung sections from K mice (upper) and KP-mice (lower) treated with ctrl or Ruxo started 1 week post tumor initiation and continued for 10 weeks. (b) Graph depicts tumor numbers per section stratified by tumor grades. Per mouse, one section was analyzed (n = 8 mice per group). (c) Left panel: representative pictures of immunohistochemical stainings for Ki67 positive cells of lungs stemming from ctrl and Ruxo treated K and KP mice. Right panel: quantitation of indicated stainings. (d) Left panel: cleaved caspase-3 positive cells of lungs of ctrl and Ruxo treated K and KP mice. Right panel: quantitation of indicated stainings (scale bars: 50 μm). (c, d) Mann–Whitney U-test, *p < 0.05, **p < 0.01, ***p < 0.001. Others: Student’s t-test. *p < 0.05, **p < 0.01, ***p < 0.001. For all graphs data presented as means ± SEM. [Color figure can be viewed at wileyonlinelibrary.com]
to promote immunosuppression and could thereby eventually enhance tumor progression.\textsuperscript{18} Thus, we addressed the effects of JAK1/2 inhibition in fully immunocompetent mouse models of autochthonous \textit{K-RAS}-driven lung AC. Therefore, we took advantage of the \textit{K-ras\textsuperscript{LSL-G12D}} (K) and \textit{K-ras\textsuperscript{LSL-G12D}:p53\textsuperscript{fl/fl}} (KP) mice. Inhalation of K and KP mice with a Cre-recombinase expressing adenovirus (Ad.Cre) triggers \textit{K-rasG12D} activation in lung epithelial cells, resulting in formation of p53 expressing (K) or deficient (KP) lung ACs. Of note, KP mice develop lung ACs showing features of advanced grade tumors.\textsuperscript{28,37} First, we validated the mouse models by isolating primary lung alveolar type II cells derived from K mice and inducing the expression of oncogenic KRAS \textit{in vitro}. Intriguingly, global gene expression analysis revealed that \textit{K-rasG12D} expression resulted in activation of the JAK–STAT pathway (Figs. S3a and S3b).\textsuperscript{27} Encouraged by these data, we treated K and KP mice 1 week after tumor

Figure 4. Legend on next page.
induction with ruxolitinib or vehicle control for a period of 10 weeks, euthanized them and analyzed their lungs. We noticed a significant decrease in tumor burden in ruxolitinib treated mice compared to vehicle-treated control mice, as indicated by reduced lung weight to body weight and tumor to lung area ratios, concomitant with reduced tumor numbers (Fig. 3a). Of note, sex differences in treatment response were not observed in our mouse models (Fig. S4a). Furthermore, grading of tumors by a pathologist (K.D.) revealed that ruxolitinib blocked the progression of K-RAS-driven lung tumors. Indeed, ruxolitinib treatment resulted in a significant reduction of high grade tumors compared to vehicle control, which reached significance for grade III tumors (Fig. 3b and Fig. S4b). No differences in body weights were observed between control and treatment groups (Figs. S4c and S4d). Similar to the engrafted human lung AC cells, ruxolitinib significantly attenuated tumor cell proliferation in these mice (Fig. 3c). Intriguingly, we observed a higher rate of tumor cell apoptosis in the vehicle treated compared to ruxolitinib group in both K and KP mouse models (Fig. 3d). Importantly, there were no differences in the expression levels of the angiogenic factors Hif1α and Vegfα between control and ruxolitinib treatment groups (Figs. S4e and S4f), suggesting that impairment of tumor cell proliferation is responsible for the reduced tumor burden upon ruxolitinib treatment in these models.

**JAK inhibition impairs progression of established K-RAS-mutated lung AC and modulates the TME**

Having demonstrated that ruxolitinib effectively reduces tumorigenesis when administered at early stages of tumor formation, we questioned whether ruxolitinib prevents progression of already established K-RAS-driven lung AC in a therapeutic setting. Therefore, we treated K mice with ruxolitinib starting 8 weeks post Ad. Cre inhalation for five consecutive weeks. In this model, we observed a reduction in lung to body weight ratios and total tumor area per lung section after ruxolitinib treatment as compared to vehicle control treatment, while tumor numbers remained unaltered (Fig. 4a). Notably, analysis of tumor to lung area ratios did not show differences between the treatment groups, most likely because total lung areas were smaller upon ruxolitinib treatment (Figs. S5a–S5c). Strikingly, grading of tumors revealed a reduction of high-grade tumors, namely tumors of grades II and III (Fig. 4b). In addition, ruxolitinib treatment of mice with established tumors also triggered significant reduction in tumor cell proliferation and increased apoptosis (Fig. 4c). Similar to the previous models, differences in mRNA expression levels of angiogenic markers Hif1α and Vegfα were not observed and body weights showed no significant differences between control and ruxolitinib treatment groups (Figs. S5d and S5e). These data suggest that ruxolitinib impairs the progression of established K-RAS-driven lung AC. Since JAK signaling plays a crucial role in regulating the immune system, we analyzed if JAK1/2 inhibition affected the composition of the TME by performing flow cytometric analysis of lung tumors. Indeed, the abundance of tumor promoting granulocytic CD45+CD11b+LY6G+ and monocytic CD45+CD11b+LY6C+ MDC38 was significantly reduced in the lungs of tumor-bearing, ruxolitinib-treated mice. Furthermore, the number of tumor promoting CD45+CD11b+CD206+ M2 macrophages was lowered upon JAK1/2 inhibition (Fig. 4d). With respect to the lymphoid lineage, our analysis revealed significantly diminished NK cell numbers upon ruxolitinib administration in tumor bearing lungs of these mice (Fig. 4d). These data are in line with a previous report using a preclinical breast cancer model.18 In addition, we observed a slight reduction in infiltrating CD8+ and CD4+ T cells upon ruxolitinib treatment, but an increase in CD4+IL17A+ Th17 cells as well as CD4+Foxp3+ regulatory T cells (Fig. 4d). Moreover, JAK inhibition lead to a significant impairment of NK and CD8+ T cell activation, but on the other hand also abrogated interferon-γ-mediated STAT1 signaling and hence reduced PD-L1 expression (Figs. 4e–4g). In summary, these data indicated that ruxolitinib altered the myeloid compartment of the TME toward an antitumorigenic state, which out-competed the suppressing effects of ruxolitinib on infiltrating cytotoxic NK and CD8+ T cells.

**JAK inhibition abrogates expression of oncogenic chemokines and cytokines**

Next, we thought to unravel the transcriptional changes, leading to the establishment of an antitumorigenic TME upon ruxolitinib treatment. Therefore, we performed RNA-seq analysis of short-term (4 days) treated tumor-bearing lungs from K mice with...
already established lung ACs. As expected, short-term administration of ruxolitinib significantly diminished activation of JAK–STAT signaling in the lung lysates of these mice (Fig. 5a and Fig. S6a). Intriguingly, GSEA analysis also revealed that ruxolitinib administration significantly reduced K-RAS activity in these lungs (Fig. 5b). Notably, within the top 350 genes negatively regulated...
by ruxolitinib (Table S6), we noticed an over-representation of factors found within GO clusters for chemokine and cytokine activity (Fig. 5c and Fig. S6b). Accordingly, most of the genes annotated in these gene sets were downregulated upon ruxolitinib treatment compared to vehicle control (Fig. 5d and Table S6). Importantly, 84 of these 109 genes downregulated by ruxolitinib were either upregulated in K-rasG12D-mutated lung alveolar type II (K) cells compared to WT cells (67 genes) or in tumor harboring lungs of KP mice compared to healthy WT lungs (52 genes). Notably, 35 hits (Tables S2 and S6) were common in all three groups (Fig. 5e and Figs. S6c and S6d). Among these 35 genes, key pro-inflammatory and pro-tumorigenic factors including Il6, Tnfa and chemokine (C-X-C motif) ligand 1 (Ccl1) were found. The anti-inflammatory properties of ruxolitinib were also observed in the long-term treatment models, as evidenced by decreased expression of these genes in treated K and KP mice (Fig. 5f).

Next, we evaluated the implication of these chemo/cytokines for human lung AC pathogenesis. Therefore, we took advantage of a meta-analysis based tool for the assessment of potential biomarkers in lung AC. Multigene classifier analysis revealed that lower mRNA expression of the signature comprising of 35 genes was associated with a better survival prognosis in these patients at a false discover rate < 1% (Fig. S6e and Table S2). Moreover, lower mRNA levels of IL6, TNFα and IL8, the human orthologue to mouse Cc11 (Fig. 5g), could be associated with a better prognosis in lung AC patients harboring K-RAS mutations. Taken together, we provide here evidence that ruxolitinib treatment successfully impairs K-RAS activity in lung tumors and leads to the establishment of an anti-inflammatory and antitumorigenic tumor microenvironment.

Discussion

Being a well-defined culprit in myeloproliferative disorders, the JAK/STAT pathway is a well-known target for pharmaceutical industry. Ruxolitinib was already Food and Drug Administration approved in 2011 based on the positive results of the COMFORT-I clinical trial. Somatic mutations rendering JAK2 constitutively active like the V617F mutation are often found in hematologic malignancies. However, solid cancers including lung cancer lack such activating somatic mutations. Nevertheless, clinical trials for lung AC patients were launched using JAK inhibitors ruxolitinib, in particular for patients with activating EGFR-mutations upstream of JAK1 and JAK2 (NCT02155465, NCT02145637, NCT02917993, NCT03450330). A recent clinical trial specifically excluding patients with EGFR-mutations showed a longer overall survival (5.9 vs. 7.5 months for placebo treated vs. ruxolitinib treated, hazard ratio = 0.877) when combining ruxolitinib and chemotherapy in non-small cell lung cancer patients (NCT02119650). However, the K-RAS mutation status of the involved patients was not disclosed. Therefore the potential benefit of a JAK1/2 inhibition for K-RAS-driven lung AC pathogenesis cannot be extrapolated. Hence, as in other clinical trials when using for example mitogen-activated protein kinase kinase 1 or rapidly accelerated fibrosarcoma inhibitors, it would be important for JAK1/2 targeting clinical trials to stratify for the K-RAS mutational status.

Here, we found increased expression of JAKs and activation of downstream STAT signaling in patients harboring advanced K-RAS lung AC. Increased JAK levels also correlated with enhanced K-RAS activity in human lung AC patient samples, suggesting that JAK/STAT signaling fuels the proliferation of K-RAS-mutated lung AC. Accordingly, ruxolitinib treatment markedly reduced tumor cell proliferation of human K-RAS-mutated A549 cells engrafted in immunodeficient NOD scid gamma mice and reduced a K-RAS activation gene signature. The engrafted tumors showed decreased expression of tumor cell-derived, pro-oncogenic cytokines IL-1β and IL-6, suggesting that ruxolitinib interferes with feed-forward cytokine signaling which promotes K-RAS tumorigenesis. Furthermore, ruxolitinib treatment resulted in tumor growth reduction in immunocompetent experimental mouse models. Ruxolitinib impaired K-RAS-driven lung AC not only at early tumor stages but also in established tumors, independently of the p53 status. Early treatment of tumors with ruxolitinib resulted in reduced tumor cell proliferation and reduced apoptosis levels. By contrast, we observed reduced cell proliferation and increased apoptosis rates in established tumors upon ruxolitinib treatment. This discrepancy can be interpreted as the result of a higher cell turnover in early tumorigenesis or by a tumor-compensatory mechanism upon
JAK1/2 inhibition present at early tumor stages. In agreement with previous reports, ruxolitinib treatment diminished tumor infiltrating CD8+ and CD4+ T cells and significantly lowered NK cell numbers but did not result in tumor metastasis, even in the absence of p53.17,18,46 In agreement with others, JAK inhibition abrogated interferon-γ-mediated STAT1 signaling and reduced PD-L1 expression levels.45 Nevertheless, NK and CD8+ T cell activation markers were reduced in lungs of ruxolitinib treated mice. Furthermore, ruxolitinib elevated numbers of tumor infiltrating CD4+IL17A+ Th17 and CD4+Foxp3+ regulatory T cells. Of note, T cells potentially play a minor role in our experimental mouse models due to a lack of tumor immunogenicity. In this sense, assessment of JAK inhibitors in T-cell-dependent lung AC experimental models44 may be a better option and can be more informative to design and interpret future and ongoing clinical trials, especially those combining JAK inhibitors and immune checkpoint blockers (e.g., NCT03425006).

On the other hand, systemic JAK inhibition triggered a slight reduction of tumor promoting M2 macrophages and significantly reduced the abundance of infiltrating granulocytic and monocytic MDSCs, which is in agreement with an induction of an anti-tumorigenic TME and the antitumor effects of ruxolitinib. Importantly, MDSCs and M2 tumor-associated macrophages not only impede tumor immune surveillance but also support tumor cell proliferation via cytokine production, and could thereby foster growth of K-RAS-driven lung AC.38,44 In line with these data, ruxolitinib treatment of mouse autochthonous lung tumors mainly affected the expression of pro-tumorigenic chemokines and cytokines. This chemokine/cytokine milieu is well-known to be a central modulator of the cancer microenvironment and it has been established as one of the hallmark drivers of cancer.46 Among these prominently downregulated chemokines and cytokines upon ruxolitinib treatment, we found ll6, Tnfα and Cxcl1. All of them are well-described pro-inflammatory and pro-tumorigenic chemo- and cytokines. Reduced IL6 levels were shown to trigger a switch in the TME toward an anti-tumoral phenotype.47 Tnfα directly endorses tumor progression and metastasis.48 Furthermore, Cxcl1 has been reported to facilitate lung cancer cell growth due to the recruitment of MDSCs and tumor associated neutrophils.3,49 Importantly, all of these factors were also found to be upregulated in K-rasG12D-mutated lung alveolar type II (K) cells compared to WT cells or in tumor harboring lungs from KP mice compared to non-tumorous lungs from KP mice. In agreement with this data, low mRNA expression levels of Il6, Tnfα and Il8 (the human orthologue to murine Cxcl1) were also associated with a better prognosis in lung AC patients harboring K-RAS mutations.39 Thus, these data indicate that Il6, Tnfα and Cxcl1 play a central role for K-RAS driven lung AC both in human and mice and provides a solid rationality for using agents blocking inflammation-driven tumorigenesis, such as ruxolitinib, to treat lung AC.7

In summary, we demonstrated here that JAK-mediated signaling is involved in progression of K-RAS-driven lung tumorigenesis and that pharmacological inhibition of JAK/STAT signaling blocks the cytokine-mediated feed-forward loop responsible for tumor cell proliferation. Additionally, JAK inhibition reprograms the TME toward an anti-inflammatory/antitumorigenic state. Therefore, our data suggest that ruxolitinib treatment represents an attractive therapeutic opportunity for treatment of K-RAS-mutated lung AC.

Acknowledgements
This project was supported by the Austrian Science Fund (FWF): P 25599-B19 to EC. H.P.M. was supported by the Initiative Krebsforschung research grant and the Fellinger Krebsforschungverein. B.G. was supported by the NVKP_16-1-2016-0037 and KH-129581 grants of the National Research, Development and Innovation Office, Hungary. R.E. was supported by the Austrian Science Fund Doktoratskolleg grant “Inflammation and Immunity” and P29222-B28, and K.D. was supported by the János Bolyai Research Scholarship, Hungarian Academy of Sciences. Funders had no role in study design, data collection and analysis, decision to publish or in the preparation of the manuscript. The authors thank Safia Zahma for help with the preparation of tissue sections and Markus Jetier and Sophia Derck (Core Facilities, Medical University of Vienna, Vienna, Austria) for help with RNA-Seq analysis.

References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:6–30.
2. Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res 2016;5:288–300.
3. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511:543–50.
4. Swanton C, Govindan R. Clinical implications of genomic discoveries in lung cancer. N Engl J Med 2016;374:1864–73.
5. Yang Z, Hackshaw A, Feng Q, et al. Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: a meta-analysis. Int J Cancer 2017;140:2805–19.
6. Roman M, Baraibar I, Lopez I, et al. KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target. Mol Cancer 2018;17:33.
7. Golay HG, Barbie DA. Targeting cytokine networks in KRAS-driven tumorigenesis. Expert Rev Anticancer Ther 2014;14:869–71.
8. Buchert M, Burns CJ, Ernst M. Targeting JAK kinase in solid tumors: emerging opportunities and challenges. Oncogene 2016;35:939–51.
9. O’Shea JJ, Schwartz DM, Villarino AV, et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med 2015;66:311–28.
10. Zhu Z, Aref AR, Cohoon TJ, et al. Inhibition of KRAS-driven tumorigenesis by interruption of an autocrine cytokine circuit. Cancer Discov 2014;4:52–65.
11. Kitajima S, Thummalapalli R, Barbie DA. Inflammation as a driver and vulnerability of KRAS-mediated oncogenesis. Semin Cell Dev Biol 2016;58:127–35.
12. Looenga BD, Hutchings D, Cherni I, et al. STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma. PLoS One 2012;7:e30820.
13. Grabner B, Schramek D, Mueller KM, et al. Disruption of STAT3 signaling promotes KRAS-induced lung tumorigenesis. Nat Commun 2015;6:6285.
14. Caetano MS, Hassane M, Van HT, et al. Sex specific function of epithelial STAT3 signaling in pathogenesis of K-ras mutant lung cancer. Nat Commun 2018;9:4589.
15. Song L, Rawal B, Nemeth JA, et al. JAK1 activates STAT3 activity in non-small cell lung cancer cells and IL-6 neutralizing antibodies can suppress
JAK1-STAT3 signaling. Mol Cancer Ther 2011;10:481–94.
16. Meissl K, Macho-Maschler S, Muller M, et al. The good and the bad faces of STAT1 in solid tumours. Cytokine 2017;89:12–20.
17. McLornan DP, Khan AA, Harrison CN. Immuno-oncology: challenges and opportunities. Nat Rev Clin Oncol 2018;15:234–48.
18. Babicki S, Arndt D, Marcu A, et al. Heatmapper: visualisation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014;15:550.
19. Heine A, Held SAE, Daecke SN, et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 2013;122:1192–202.
20. Luo N, Formisano L, Gonzalez-Ericsson PI, et al. Melanoma response to anti-PD-1 immunotherapy requires JAK1 signaling, but not JAK2. Oncoimmunology 2018;7:e1438106.
21. Meissl K, Macho-Maschler S, Muller M, et al. Decreased NK cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models. Nat Commun 2016;7:12258.
22. Girard L, Rodriguez-Canales J, Behrens C, et al. The JAK1-STAT3 signaling pathway regulates the IL-6/JAK/STAT3 signalling axis in cancer. Mol Cancer Ther 2015;10:370–9.
23. Campbell JD, Alexandrov A, Kim J, et al. Distinct genomic signature as an aid to the histologic classification of non-small-cell lung cancer. Cell Prolif 2016;49:403–15.
24. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545–50.
25. Gyeney B, Surowiak P, Budczies J, et al. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One 2013;8:e82241.
26. Ali A, Brown V, Denley S, et al. Expression of KOC, S100P, mesothelin and MUC1 in pancreaticobiliary adenocarcinomas: development and utility of a potential diagnostic immunohistochemistry panel. BMC Clin Pathol 2014;14:35.
27. Moell HP, Pranz K, Musteau M, et al. Aflatinib restrains K-RAS-driven lung tumorigenesis. Sci Transl Med 2018;10:eaae2301.
28. Girard L, Rodriguez-Canales J, Behrens C, et al. The JAK1-STAT3 signaling pathway regulates the IL-6/JAK/STAT3 signalling axis in cancer. Mol Cancer Ther 2015;10:370–9.
29. Ali A, Brown V, Denley S, et al. Expression of KOC, S100P, mesothelin and MUC1 in pancreaticobiliary adenocarcinomas: development and utility of a potential diagnostic immunohistochemistry panel. BMC Clin Pathol 2014;14:35.
30. Moell HP, Pranz K, Musteau M, et al. Aflatinib restrains K-RAS-driven lung tumorigenesis. Sci Transl Med 2018;10:eaae2301.
31. Kuleshov MV, Jones MR, Rouillard AD, et al. ActiVenn: a web-based tool for the analysis of sets of differentially regulated target genes and sample integrity: BestKeeper--Excel-based tool using pair-wise correlations. Biotechnol Lett 2004;26:509–15.
32. Heberle H, Meirelles GV, da Silva FR, et al. Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper--Excel-based tool using pair-wise correlations. Biotechnol Lett 2004;26:509–15.
33. Babicki S, Arndt D, Marcu A, et al. Heatmapper: a web-based tool for the analysis of sets through Venn diagrams. BMC Bioinformatics 2015;16:169.
34. Pfaffl MW, Tichopad A, Prgomet C, et al. Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper--Excel-based tool using pair-wise correlations. Biotechnol Lett 2004;26:509–15.
35. Xue C, Xie J, Zhao D, et al. The JAK1/STAT3 signaling pathway regulates angiogenesis in an endothelial cell/adipose-derived stromal cell co-culture, 3D gel model. Cell Prolif 2017;50:e12307.
36. Hidalgo M, Amant F, Biankin AV, et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 2005;65:10280–8.
37. Jackson EL, Olive KP, Tuveson DA, et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 2005;65:10280–8.